This is a speculative, balance-sheet-driven story masquerading as a growth equity. With no P/E, no Forward P/E, and EPS at -4.3, the market cannot value BNTC on earnings because there are none; instead, investors are paying 2.1x book value for a company with a -23.50% operating margin and ROIC of -23.40%. The one standout metric is an Altman Z-Score of 69.4 and a Current Ratio of 67.7, which signal extreme balance sheet safety and negligible near-term bankruptcy risk despite ongoing losses. At a $392M market cap, this is not priced like a distressed biotech, but it is clearly priced on optionality rather than fundamentals, making it a high-risk, high-duration bet rather than a traditional GARP opportunity.